Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation
Francesca M. Trovato,Rabiya Zia,Salvatore Napoli,Kate Wolfer,Xiaohong Huang,Phillip E. Morgan,Hannah Husbyn,Marwa Elgosbi,Manuele Lucangeli,Rosa Miquel,Ian Wilson,Nigel David Heaton,Michael A. Heneghan,Georg Auzinger,Charalambos G. Antoniades,Julia A. Wendon,Vishal C. Patel,Muireann Coen,Evangelos Triantafyllou,Mark J. McPhail
DOI: https://doi.org/10.1002/hep.31738
IF: 17.298
2021-06-15
Hepatology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Acute‐on‐chronic liver failure (ACLF) is characterised by systemic inflammation, monocyte dysfunction, and susceptibility to infection. Lysophosphatidylcholines (LPCs) are immune‐active lipids whose metabolic regulation and effect on monocyte function in ACLF is unknown.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approaches and Results</h3><p>Three hundred and forty‐two subjects were recruited and characterised for blood lipid, cytokines, phospholipase (PLA) and autotaxin (ATX) concentration. Peripheral blood mononuclear cells and CD14+‐monocytes were cultured with LPC, or its autotaxin(ATX)‐derived product lysophosphatidic acid (LPA), with or without lipopolysaccharide stimulation and assessed for surface marker phenotype, cytokines production, ATX and LPA‐receptor expression and phagocytosis. Hepatic ATX expression was determined by immunohistochemistry. Healthy volunteers, patients with sepsis or acute liver failure served as controls. ACLF serum was depleted in LPCs with upregulated LPA levels. Patients who died had lower LPC levels than survivors (AUROC 0.94, p<0.001). Patients with high‐grade ACLF had the lowest LPC concentrations and these rose over the first 3 days of admission. ATX concentrations were higher in patients with AD and ACLF and correlated with MELD, CLIF‐SOFA and LPC/LPA concentrations. Reduction in LPC correlated with higher monocyte MerTK and CD163 expression. Plasma ATX concentrations rose dynamically during ACLF evolution, correlating with IL‐6 and TNF‐α and were associated with increased hepatocyte ATX expression. ACLF patients had lower HLA‐DR and higher CD163/MerTK monocyte expression than controls; both CD163/MerTK expression levels were reduced in ACLF <i>ex‐vivo</i> following LPA, but not LPC, treatment. LPA induced up‐regulation of pro‐inflammatory cytokines by CD14<sup>+</sup> cells without increasing phagocytic capacity. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>ATX upregulation in ACLF promotes LPA production from LPC. LPA suppresses MerTK/CD163 expression and increases monocyte pro‐inflammatory cytokine production. This metabolic pathway could be investigated to therapeutically reprogram monocytes in ACLF.</p></section>
gastroenterology & hepatology